A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze)
Loibl S, Jackisch C, Seiler S, Rastogi P, Huober L, Denkert C, Schneeweiss A, Hanusch C, Fasching P, Blohmer JU, Untch M, Rhiem K, Solbach C, Nekljudova V, Costantino J, Wolmark N, Geyer C (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: KARGER
City/Town: BASEL
Pages Range: 24-25
Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT
DOI: 10.1016/j.annonc.2020.08.369
Authors with CRIS profile
Involved external institutions
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universität zu Köln
Germany (DE)
University of Pittsburgh
United States (USA) (US)
Philipps-Universität Marburg
Germany (DE)
Orlando Health
United States (USA) (US)
HELIOS Kliniken
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Virginia Commonwealth University (VCU)
United States (USA) (US)
Sana Klinikum Offenbach
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Germany (DE)
Universität zu Köln
Germany (DE)
University of Pittsburgh
United States (USA) (US)
Philipps-Universität Marburg
Germany (DE)
Orlando Health
United States (USA) (US)
HELIOS Kliniken
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Virginia Commonwealth University (VCU)
United States (USA) (US)
Sana Klinikum Offenbach
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
How to cite
APA:
Loibl, S., Jackisch, C., Seiler, S., Rastogi, P., Huober, L., Denkert, C.,... Geyer, C. (2020). A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze). In ONCOLOGY RESEARCH AND TREATMENT (pp. 24-25). BASEL: KARGER.
MLA:
Loibl, Sibylle, et al. "A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2020. 24-25.
BibTeX: Download